| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0973b70303a6689b2d3eca1118129321 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 |
| filingDate |
2001-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb9c64305b634d6ee0aa814f5ae5ff32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_659c112e619a0332126d7598c958e97e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f6fb2802d52791ced45e33b1ef190b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3432f65203340f3ebd126e70fcc8c72b |
| publicationDate |
2001-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0195877-A2 |
| titleOfInvention |
Porous celecoxib matrices and methods of manufacture thereof |
| abstract |
Celecoxib is provided in a porous matrix form wherein the dissolution rate of the drug is enhanced when the matrix is contacted with an aqueous medium. The porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of celecoxib having a mean diameter between about 0.01 and 5 νm and a total surface area greater than about 0.5 m2/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL. The porous celecoxib matrices preferably are made using a process that includes: (i) dissolving celecoxib in a volatile solvent to form a drug solution; (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution; and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of celecoxib. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016198393-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107949371-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9757464-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10675602-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017103677-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10307429-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11364203-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10300443-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10688110-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9724664-B2 |
| priorityDate |
2000-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |